The Swiss major's biggest seller rose 12% in the second quarter and while COVID-19 had an impact, and competition is on the rise, Cosentyx is still outpacing the market overall in psoriasis, while rheumatology should drive future growth.
Reports of the demise of Novartis AG's Cosentyx appear to be greatly exaggerated given that sales of the blockbuster are continuing to rise despite fierce competition and the Swiss major is looking to secure approvals for more indications.
Second-quarter sales of Cosentyx (secukinumab), which is approved for psoriasis, psoriatic arthritis (PsA) and spondyloarthritis (SpA) and is comfortably Novartis's...
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
The Belgian drugmaker is boosting its biologics capacity over the pond.
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.
The Phase III trial met the primary endpoint of time to clinical worsening in patients newly diagnosed with pulmonary arterial hypertension.
As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.
The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.
